Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41
- PMID: 35412133
- DOI: 10.1007/978-981-16-8702-0_3
Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41
Abstract
Interrupting early events in the virus life cycle, such as those prior to the formation of provirus, could effectively prevent HIV-1 infection. HIV-1 entry into host cells is mediated by the envelope glycoprotein (Env) trimer, which is composed of three gp120 exterior glycoproteins and three gp41 transmembrane glycoproteins. Hence, the development of novel inhibitors targeting these two glycoproteins could hold the key to early inhibition of HIV-1 infection. Small-molecule entry inhibitors targeting early events in the virus life cycle comprise a well-established class of useful drugs. Many libraries of small-molecule inhibitors have been established to screen potential drug candidates for a variety of targets based on computer docking, FRET, or peptide-linked assay. This chapter reviews the mechanisms of some small-molecule inhibitors targeting HIV-1 gp120 and gp41 and corresponding high-efficiency screening strategies for potential small-molecule inhibitors.
Keywords: Mechanisms of action; Screening strategies; Small-molecule inhibitors; Virus.
© 2022. Springer Nature Singapore Pte Ltd.
Similar articles
-
Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.J Virol. 2019 May 15;93(11):e00142-19. doi: 10.1128/JVI.00142-19. Print 2019 Jun 1. J Virol. 2019. PMID: 30894471 Free PMC article.
-
Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.Curr Top Med Chem. 2016;16(10):1074-90. doi: 10.2174/1568026615666150901114527. Curr Top Med Chem. 2016. PMID: 26324044 Free PMC article. Review.
-
Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jun;27(6):707-719. doi: 10.1080/13543776.2017.1281249. Epub 2017 Jan 19. Expert Opin Ther Pat. 2017. PMID: 28076686 Review.
-
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.J Virol. 2017 Jan 18;91(3):e01880-16. doi: 10.1128/JVI.01880-16. Print 2017 Feb 1. J Virol. 2017. PMID: 27881646 Free PMC article.
-
HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.Chem Biodivers. 2018 Oct;15(10):e1800159. doi: 10.1002/cbdv.201800159. Epub 2018 Sep 21. Chem Biodivers. 2018. PMID: 30027572 Review.
References
-
- Armand-Ugon M, Clotet-Codina I, Tintori C, Manetti F, Clotet B, Botta M, Este JA (2005) The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 343(1):141–149. https://doi.org/10.1016/j.virol.2005.08.007 - DOI - PubMed
-
- Caffrey M (2001) Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop. BBA-Mol Basis Dis 1536(2–3):116–122. https://doi.org/10.1016/S0925-4439(01)00042-4 - DOI
-
- Cai L, Gochin M (2007) A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. Antimicrob Agents Chemother 51(7):2388–2395. https://doi.org/10.1128/AAC.00150-07 - DOI - PubMed - PMC
-
- Case MA, Ghadiri MR, Mutz MW, McLendon GL (1998) Stereoselection in designed three-helix bundle metalloproteins. Chirality 10(1–2):35–40. https://doi.org/10.1002/chir.7 - DOI - PubMed
-
- Chan DC, Kim PS (1998) HIV entry and its inhibition. Cell 93(5):681–684. https://doi.org/10.1016/S0092-8674(00)81430-0 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical